Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "actavis" 10 mg/ml koncentrat til infusionsvæske, opløsning
actavis group ptc ehf. - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "fresenius kabi" 10 mg/ml koncentrat til infusionsvæske, opløsning
fresenius kabi ab - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "mylan" 10 mg/ml koncentrat til infusionsvæske, opløsning
mylan ireland limited - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "hospira" 10 mg/ml koncentrat til infusionsvæske, opløsning
hospira nordic ab - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "pfizer" 10 mg/ml koncentrat til infusionsvæske, opløsning
pfizer aps - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "ebewe" 10 mg/ml koncentrat til infusionsvæske, opløsning
ebewe pharma ges.m.b.h. nfg. kg - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Danmark -
dansk -
Lægemiddelstyrelsen (Danish Medicines Agency)
carboplatin "accord" 10 mg/ml koncentrat til infusionsvæske, opløsning
accord healthcare b.v. - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
tremelimumab astrazeneca
astrazeneca ab - tremelimumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
iressa
astrazeneca ab - gefitinib - carcinom, ikke-småcellet lunge - antineoplastiske midler - iressa er indiceret til behandling af voksne patienter med lokalt fremskreden eller metastatisk ikke-small-cell lung cancer med aktiverende mutationer af epidermal-growth-factor-receptor tyrosin kinase.
Den Europæiske Union -
dansk -
EMA (European Medicines Agency)
imfinzi
astrazeneca ab - durvalumab - carcinom, ikke-småcellet lunge - antineoplastiske midler - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).